Illumina Synergy SomaLogic is now part of Illumina, creating immediate cross-sell opportunities into Illumina’s existing customer base for integrated proteomics and sequencing workflows, including protein prep and SOMAmer-based library solutions.

Scalable Proteomics The SomaScan platform scales with precision, enabling large-scale biomarker discovery and precision medicine programs; target pharma, biotech, and CROs needing enterprise-grade proteomics at scale.

Financial Backing The strategic acquisition brings strong liquidity and growth capital, enabling accelerated expansion, R&D, and partnerships to grow the installed base and pursue larger deals with pharma and research organizations.

Integrated Workflows Leverage SOMAmer reagents and protein prep royalty assets to offer end-to-end proteomics workflows that complement sequencing and genomic data, appealing to drug discovery and clinical research programs.

Ecosystem Upsell Target Illumina customers and partners with cross-sell opportunities around SomaLogic capabilities and KREX offerings to unlock combined genomics-proteomics value.